{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T12:15:56Z","timestamp":1778847356150,"version":"3.51.4"},"reference-count":56,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2007,5,1]],"date-time":"2007-05-01T00:00:00Z","timestamp":1177977600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diagnostic Microbiology and Infectious Disease"],"published-print":{"date-parts":[[2007,5]]},"DOI":"10.1016\/j.diagmicrobio.2007.01.019","type":"journal-article","created":{"date-parts":[[2007,4,6]],"date-time":"2007-04-06T15:59:52Z","timestamp":1175875192000},"page":"1-7","source":"Crossref","is-referenced-by-count":9,"title":["Garenoxacin activity against isolates form patients hospitalized with community-acquired pneumonia and multidrug-resistant Streptococcus pneumoniae"],"prefix":"10.1016","volume":"58","author":[{"given":"Ronald N.","family":"Jones","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helio S.","family":"Sader","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew G.","family":"Stilwell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas R.","family":"Fritsche","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.diagmicrobio.2007.01.019_bib2","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.diagmicrobio.2004.07.008","article-title":"Bactericidal activity of garenoxacin tested by kill-curve methodology against wild type and QRDR mutant strains of Streptococcus pneumoniae","volume":"50","author":"Anderegg","year":"2004","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2007.01.019_bib1","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S0732-8893(03)00039-7","article-title":"Re-evaluation of quality control guidelines for gatifloxacin and garenoxacin (BMS284756) when susceptibility testing Haemophilus influenzae and Streptococcus pneumoniae","volume":"46","author":"Anderegg","year":"2003","journal-title":"Diagn. Microbiol. Infect. Dis."},{"issue":"Suppl 1","key":"10.1016\/j.diagmicrobio.2007.01.019_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jac\/dkg212","article-title":"Development of the quinolones","volume":"51","author":"Andersson","year":"2003","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.diagmicrobio.2007.01.019_bib4","doi-asserted-by":"crossref","first-page":"3935","DOI":"10.1128\/AAC.47.12.3935-3941.2003","article-title":"Pharmacodynamics of the new des-f(6)-quinolone garenoxacin in a murine thigh infection model","volume":"47","author":"Andes","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2007.01.019_bib5","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1111\/j.1469-0691.2006.01387.x","article-title":"The effect of implementing the British Thoracic Society community-acquired pneumonia guidelines on antibiotic prescribing and costs in a UK teaching hospital","volume":"12","author":"Barlow","year":"2006","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.diagmicrobio.2007.01.019_bib6","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0732-8893(03)00016-6","article-title":"Five-year analysis of Haemophilus influenzae isolates with reduced susceptibility to fluoroquinolones: prevalence results from the SENTRY antimicrobial surveillance program","volume":"46","author":"Biedenbach","year":"2003","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2007.01.019_bib7","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1086\/498119","article-title":"Antibiotic prescription for community-acquired pneumonia in the intensive care unit: impact of adherence to Infectious Diseases Society of America guidelines on survival","volume":"41","author":"Bodi","year":"2005","journal-title":"Clin. Infect. Dis."},{"issue":"Suppl 4","key":"10.1016\/j.diagmicrobio.2007.01.019_bib8","first-page":"IV1","article-title":"BTS guidelines for the management of community acquired pneumonia in adults","volume":"56","year":"2001","journal-title":"Thorax"},{"issue":"Suppl 3","key":"10.1016\/j.diagmicrobio.2007.01.019_bib9","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1469-0691.2006.01392.x","article-title":"Clinical experience in the management of community-acquired pneumonia: lessons from the use of fluoroquinolones","volume":"12","author":"Carratala","year":"2006","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.diagmicrobio.2007.01.019_bib10","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1056\/NEJM199907223410403","article-title":"Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Canadian Bacterial Surveillance Network","volume":"341","author":"Chen","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.diagmicrobio.2007.01.019_bib11","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1046\/j.1469-0691.2002.00405.x","article-title":"Single- and multistep selection study of the antipneumococcal activity of BMS-284756 compared to ciprofloxacin, levofloxacin, trovafloxacin and moxifloxacin","volume":"8","author":"Clark","year":"2002","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.diagmicrobio.2007.01.019_bib12","series-title":"M7-A7, Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard","author":"Clinical and Laboratory Standards Institute (CLSI)","year":"2006"},{"key":"10.1016\/j.diagmicrobio.2007.01.019_bib13","series-title":"Clinical and Laboratory Standards Institute. M100-S16, Performance Standards for Antimicrobial Susceptibility Testing; Sixteenth Informational Supplement","author":"Clinical and Laboratory Standards Institute (CLSI)","year":"2006"},{"key":"10.1016\/j.diagmicrobio.2007.01.019_bib14","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1086\/505871","article-title":"Macrolide resistance in bacteremic pneumococcal disease: implications for patient management","volume":"43","author":"Daneman","year":"2006","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2007.01.019_bib15","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1093\/jac\/dkf145","article-title":"Comparative in vitro activity of garenoxacin against Chlamydia spp.","volume":"50","author":"Donati","year":"2002","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.diagmicrobio.2007.01.019_bib17","doi-asserted-by":"crossref","first-page":"5024","DOI":"10.1128\/AAC.49.12.5024-5032.2005","article-title":"In vitro activity of linezolid against key gram-positive organisms isolated in the United States: results of the LEADER 2004 surveillance program","volume":"49","author":"Draghi","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2007.01.019_bib16","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.ijantimicag.2006.09.002","article-title":"Geographically-based evaluation of multidrug resistance trends among Streptococcus pneumoniae in the USA: findings of the FAST surveillance initiative (2003\u20132004)","volume":"28","author":"Draghi","year":"2006","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.diagmicrobio.2007.01.019_bib18","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S0732-8893(01)00285-1","article-title":"In vitro susceptibility study of BMS-284756 against Legionella species","volume":"41","author":"Dubois","year":"2001","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2007.01.019_bib19","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1093\/jac\/48.5.667","article-title":"BMS-284756 (T-3811ME) a new fluoroquinolone: in vitro activity against Legionella, efficacy in a guinea pig model of L. pneumophila pneumonia and pharmacokinetics in guinea pigs","volume":"48","author":"Edelstein","year":"2001","journal-title":"J. Antimicrob. Chemother."},{"issue":"Suppl 3","key":"10.1016\/j.diagmicrobio.2007.01.019_bib20","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/j.1469-0691.2006.01395.x","article-title":"Clinical implications and treatment of multiresistant Streptococcus pneumoniae pneumonia","volume":"12","author":"File","year":"2006","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.diagmicrobio.2007.01.019_bib21","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1378\/chest.125.5.1888","article-title":"Guidelines for empiric antimicrobial prescribing in community-acquired pneumonia","volume":"125","author":"File","year":"2004","journal-title":"Chest"},{"key":"10.1016\/j.diagmicrobio.2007.01.019_bib22","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1093\/jac\/48.5.735-a","article-title":"Activity of the novel des-fluoro(6) quinolone BMS-284756 against methicillin-susceptible and -resistant staphylococci","volume":"48","author":"Fung-Tomc","year":"2001","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.diagmicrobio.2007.01.019_bib23","doi-asserted-by":"crossref","first-page":"3351","DOI":"10.1128\/AAC.44.12.3351-3356.2000","article-title":"Antibacterial spectrum of a novel des-fluoro(6) quinolone, BMS-284756","volume":"44","author":"Fung-Tomc","year":"2000","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2007.01.019_bib25","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1592\/phco.22.3.160.33556","article-title":"Effect of a high-fat meal on the pharmacokinetics of the des-F(6)-quinolone BMS-284756","volume":"22","author":"Gajjar","year":"2002","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.diagmicrobio.2007.01.019_bib24","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1128\/AAC.47.7.2256-2263.2003","article-title":"Multiple-dose safety and pharmacokinetics of oral garenoxacin in healthy subjects","volume":"47","author":"Gajjar","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2007.01.019_bib26","doi-asserted-by":"crossref","first-page":"3967","DOI":"10.1128\/JCM.41.8.3967-3969.2003","article-title":"Commercial broth microdilution panel validation and reproducibility trials for garenoxacin (BMS-284756), a novel desfluoroquinolone","volume":"41","author":"Gordon","year":"2003","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.diagmicrobio.2007.01.019_bib27","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1128\/AAC.45.10.2865-2870.2001","article-title":"Selection and genetic characterization of Streptococcus pneumoniae mutants resistant to the des-F(6) quinolone BMS-284756","volume":"45","author":"Hartman-Neumann","year":"2001","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2007.01.019_bib28","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1128\/AAC.45.2.589-592.2001","article-title":"Comparative antianaerobic activity of BMS 284756","volume":"45","author":"Hoellman","year":"2001","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2007.01.019_bib29","doi-asserted-by":"crossref","first-page":"3370","DOI":"10.1128\/AAC.46.11.3370-3380.2002","article-title":"Dual targeting of DNA gyrase and topoisomerase IV: target interactions of garenoxacin (BMS-284756, T-3811ME), a new desfluoroquinolone","volume":"46","author":"Ince","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2007.01.019_bib30","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1086\/425615","article-title":"The burden of community-acquired pneumonia in seniors: results of a population-based study","volume":"39","author":"Jackson","year":"2004","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2007.01.019_bib31","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S0732-8893(03)00002-6","article-title":"Comparative activity of garenoxacin (BMS 284756), a novel desfluoroquinolone, tested against 8,331 isolates from community-acquired respiratory tract infections: North American results from the SENTRY Antimicrobial Surveillance Program (1999\u20132001)","volume":"45","author":"Jones","year":"2003","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2007.01.019_bib32","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0732-8893(00)00233-9","article-title":"Activity and spectrum of BMS 284756, a new des-F (6) quinolone, tested against strains of ciprofloxacin-resistant Gram-positive cocci","volume":"39","author":"Jones","year":"2001","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2007.01.019_bib33","doi-asserted-by":"crossref","first-page":"3320","DOI":"10.1128\/AAC.46.10.3320-3322.2002","article-title":"Effects of the Des-F(6)-quinolone garenoxacin (BMS-284756), in comparison to those of ciprofloxacin and ofloxacin, on joint cartilage in immature rats","volume":"46","author":"Kappel","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2007.01.019_bib34","doi-asserted-by":"crossref","first-page":"4460","DOI":"10.1128\/AAC.48.11.4460-4462.2004","article-title":"Quinolone-resistant Haemophilus influenzae: determination of mutant selection window for ciprofloxacin, garenoxacin, levofloxacin, and moxifloxacin","volume":"48","author":"Li","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2007.01.019_bib35","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1093\/jac\/dkg017","article-title":"Impact of AUC\/MIC ratios on the pharmacodynamics of the des-F(6) quinolone garenoxacin (BMS-284756) is similar to other fluoroquinolones","volume":"51","author":"Lister","year":"2003","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.diagmicrobio.2007.01.019_bib36","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1128\/AAC.46.2.517-518.2002","article-title":"In vitro activities of BMS-284756 against Chlamydia trachomatis and recent clinical isolates of Chlamydia pneumoniae","volume":"46","author":"Malay","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2007.01.019_bib37","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1086\/313959","article-title":"Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society. The Canadian Community-Acquired Pneumonia Working Group","volume":"31","author":"Mandell","year":"2000","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2007.01.019_bib38","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1086\/380488","article-title":"Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults","volume":"37","author":"Mandell","year":"2003","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2007.01.019_bib39","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.otohns.2005.12.021","article-title":"Acute bacterial rhinosinusitis: a review of U.S. treatment guidelines","volume":"135","author":"Marple","year":"2006","journal-title":"Otolaryngol. Head Neck Surg."},{"key":"10.1016\/j.diagmicrobio.2007.01.019_bib40","doi-asserted-by":"crossref","first-page":"2692","DOI":"10.1128\/AAC.47.8.2692-2695.2003","article-title":"Fluoroquinolone-resistant Streptococcus pneumoniae in Spain: activities of garenoxacin against clinical isolates including strains with altered topoisomerases","volume":"47","author":"Morosini","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2007.01.019_bib41","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1086\/507699","article-title":"Effect of pneumococcal vaccination: a comparison of vaccination rates in patients with bacteremic and nonbacteremic pneumococcal pneumonia","volume":"43","author":"Musher","year":"2006","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2007.01.019_bib42","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1128\/AAC.47.5.1630-1635.2003","article-title":"Pharmacodynamics of a novel des-F(6)-quinolone, BMS-284756, against Streptococcus pneumoniae in the thigh infection model","volume":"47","author":"Nicolau","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2007.01.019_bib43","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1164\/ajrccm.163.7.at1010","article-title":"Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention","volume":"163","author":"Niederman","year":"2001","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.diagmicrobio.2007.01.019_bib44","article-title":"Comparative susceptibility patterns of levofloxacin and other agents against pediatric respiratory tract isolates of Streptococcus pneumoniae (SP), Abstr 254","author":"Noel","year":"2006"},{"key":"10.1016\/j.diagmicrobio.2007.01.019_bib45","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1111\/j.1469-0691.2005.01286.x","article-title":"Predicted effects on antibiotic use following the introduction of British or North American guidelines for community-acquired pneumonia in The Netherlands","volume":"11","author":"Oosterheert","year":"2005","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.diagmicrobio.2007.01.019_bib46","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1128\/AAC.40.10.2321","article-title":"Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae","volume":"40","author":"Pan","year":"1996","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2007.01.019_bib47","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0732-8893(01)00247-4","article-title":"Activity of BMS284756 (T-3811) tested against anaerobic bacteria, Campylobacter jejuni, Helicobacter pylori and Legionella spp.","volume":"40","author":"Rhomberg","year":"2001","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2007.01.019_bib48","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1093\/jac\/49.4.698","article-title":"In vitro activity of the novel des-F(6) quinolone BMS-284756 against genetically characterized clinical streptococcal isolates, including isolates with reduced quinolone susceptibility","volume":"49","author":"Schmitz","year":"2002","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.diagmicrobio.2007.01.019_bib49","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.otohns.2003.12.003","article-title":"Antimicrobial treatment guidelines for acute bacterial rhinosinusitis. Executive summary","volume":"130","author":"Sinus and Allergy Health Partnership","year":"2004","journal-title":"Otolaryngol. Head Neck Surg."},{"key":"10.1016\/j.diagmicrobio.2007.01.019_bib50","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1128\/AAC.43.5.1077","article-title":"In vitro and in vivo antimicrobial activities of T-3811ME, a novel des-F(6)-quinolone","volume":"43","author":"Takahata","year":"1999","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2007.01.019_bib51","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1128\/AAC.45.1.312-315.2001","article-title":"In vitro and in vivo efficacies of T-3811ME (BMS-284756) against Mycoplasma pneumoniae","volume":"45","author":"Takahata","year":"2001","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2007.01.019_bib52","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/jac\/dkf081","article-title":"In vitro activity of a novel des-fluoro(6) quinolone, garenoxacin (BMS-284756), against rapidly growing mycobacteria and Nocardia isolates","volume":"50","author":"Valera","year":"2002","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.diagmicrobio.2007.01.019_bib53","doi-asserted-by":"crossref","first-page":"4766","DOI":"10.1128\/AAC.48.12.4766-4777.2004","article-title":"Population pharmacokinetics and pharmacodynamics of garenoxacin in patients with community-acquired respiratory tract infections","volume":"48","author":"Van Wart","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2007.01.019_bib54","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1128\/AAC.47.1.161-165.2003","article-title":"In vitro susceptibilities to and bactericidal activities of garenoxacin (BMS-284756) and other antimicrobial agents against human mycoplasmas and ureaplasmas","volume":"47","author":"Waites","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2007.01.019_bib55","doi-asserted-by":"crossref","first-page":"3660","DOI":"10.1128\/AAC.45.12.3660-3662.2001","article-title":"Mechanism of action of the des-F(6) quinolone BMS-284756 measured by supercoiling inhibition and cleavable complex assays","volume":"45","author":"Wu","year":"2001","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2007.01.019_bib56","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1093\/jac\/dkl159","article-title":"Pharmacodynamic activity of garenoxacin against ciprofloxacin-resistant Streptococcus pneumoniae","volume":"58","author":"Zhanel","year":"2006","journal-title":"J. Antimicrob. Chemother."}],"container-title":["Diagnostic Microbiology and Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889307000557?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889307000557?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,27]],"date-time":"2019-04-27T05:36:18Z","timestamp":1556343378000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0732889307000557"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,5]]},"references-count":56,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007,5]]}},"alternative-id":["S0732889307000557"],"URL":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2007.01.019","relation":{},"ISSN":["0732-8893"],"issn-type":[{"value":"0732-8893","type":"print"}],"subject":[],"published":{"date-parts":[[2007,5]]}}}